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results	 in	 the	 absence	 of	 an	 evident	 intra-abdominal,	 surgically	
treatable	 source	 of	 infection.1	 It	 is	 a	 different	 clinical	 entity	 than	
spontaneous	 bacterial	 peritonitis	 (SBP),	 which	 is	 characterized	 by	









tial	 underlying	 pathophysiological	 mechanisms.	 The	 most	 com-
mon	 theory	 implicates	 that	 the	bacterial	 colonization	of	 ascites	
is	caused	by	bacterial	translocation	from	the	intestinal	 lumen	or	
by	 secondary	 translocation	 from	 a	 concomitant	 infection	 from	
extraintestinal	sites	(eg,	urogenital	or	respiratory	tract).	The	ab-




text,	 the	 term	 ‘symptomatic	 bacterascites’	 has	 been	 introduced	
for	patients	with	bacterascites	and	clinical	symptoms	of	infection,	
in	 order	 to	 identify	 those	 patients	who	may	 require	 treatment.	
Furthermore,	 bacterascites	 caused	 by	 commensal	 skin	 bacteria	
has	 been	 attributed	 to	 exogenous	 contamination	 of	 the	 ascitic	
fluid	 sample	 and	 bacterascites	with	multiple	 pathogens	may	 be	
caused	by	traumatic	paracentesis.2,3	The	indication	for	antibiotic	
treatment	of	bacterascites	is	generally	regarded	to	be	dependent	
on	 the	 supposed	pathophysiological	mechanism	and	 the	 clinical	
situation.
The	AASLD	 practice	 guideline	 regarding	 the	management	 of	
ascites	 states	 that	 patients	with	 ascites	 and	 convincing	 signs	 or	




The	EASL	 clinical	 practice	 guideline	endorses	 this	 recommenda-
tion	 and	 further	 states	 asymptomatic	 patients	 should	 undergo	









was	 to	 assess	 the	 clinical	 characteristics,	microbiological	 findings,	
and	 clinical	 course	 in	 consecutive	 patients	 diagnosed	with	 bacte-
rascites.	We	 further	 attempted	 to	 study	 the	 prognostic	 impact	 of	
bacterascites	 in	comparison	to	SBP,	and	to	define	the	most	 logical	
therapeutic	approach.
2  | PATIENTS AND METHODS
2.1 | Study design and data collection
All	consecutive	ascites	cultures	performed	in	patients	with	advanced	
chronic	 liver	 disease	 between	 January	 2003	 and	 August	 2016	 at	
Erasmus	 MC,	 University	 Medical	 Center,	 were	 retrospectively	
reviewed	to	identify	patients	fulfilling	the	diagnostic	criteria	for	bac-









Paracentesis	 was	 performed	 in	 patients	 with	 new-	onset	 asci-
tes,	 clinical	 deterioration,	 and	 large-	volume	 removal	 in	 refractory	
ascites.9	White	 blood	 cell	 (WBC)	 and	 PMN	 count	 in	 ascites	 were	
automatically	determined	and	aerobic	and	anaerobic	blood	culture	
bottles	 (Bactec®)	 were	 used	 for	 bacterial	 cultures.	 Blood	 cultures	
taken	within	two	hours	before	or	after	ascites	cultures	were	consid-
ered	to	be	concomitant.





a	 previous	 publication.10	 In	 order	 to	 create	 homogenous	 groups	
for	 survival	 analyses,	patients	with	both	episodes	of	bacterascites	
and	SBP	were	 categorized	as	SBP	when	 the	 first	 ascites	 infection	
was	 SBP	 or	 bacterascites	 developed	within	 48	h	 to	 SBP.	 Patients	






peritonitis	 (ALL)	 AND	 (outcome	 (ALL)	 OR	 mortality	 (ALL))	 AND	
prognos*	 (ALL).	 The	 studies	 were	 reviewed	 and	 included	 when	
the	following	criteria	were	met:	(1)	observational	studies,	(b)	study	
population	consisted	of	patients	with	SBP	defined	as	a	PMN	count	
of	 250/μL	or	 greater	 in	 ascites,	 (c)	minimum	 study	population	of	
50	 adult	 patients,	 (d)	 reporting	 survival	 analysis	 and	 1-	month	 or	
Key Points
•	 	Bacterascites	is	an	ascitic	fluid	infection	with	a	positive	
bacterial	 culture	 and	 PMN	 count	 below	 250/μL.	





confirm	 the	 prognostic	 importance	 of	 presence	 of	
symptoms	at	the	time	of	diagnosis.
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in-	hospital	mortality	rate,	and	(e)	written	in	English.	Interventional	
studies	 (eg,	 randomized	controlled	 trials),	 studies	with	a	selected	
population	(eg,	HIV	patients),	and	abstracts	were	excluded.	Study	





dence	 for	an	 intra-abdominal	 source	of	 infection.1	 Infection	acquisi-
tion	was	categorized	as	nosocomial	(infection	was	detected	after	48	h	
after	hospital	admission),	healthcare-	associated	 (<48	h	after	hospital	






















survival	 analysis.	 Follow-	up	 started	 at	 the	 time	 of	 the	 first	 ascitic	
fluid	analysis.	A	multivariable	logistic	regression	analysis	was	carried	
out	to	identify	predictors	for	treatment	of	bacterascites,	a	multivari-
able	 logistic	 regression	 analysis	 in	 the	 untreated	 patient	 group	 to	










Cox’s	 regression.	The	 regression	models	were	employed	using	 the	
backward	stepwise	selection	method	with	removal	testing	based	on	













































GI,	 gastrointestinal;	HCC,	 hepatocellular	 carcinoma;	 INR,	 international	
normalized	 ratio;	 IQR,	 interquartile	 range;	MELD,	model	 for	end-	stage	
liver	disease;	NASH,	nonalcoholic	steatohepatitis;	PMN,	polymorphonu-
clear	neutrophil;	SD,	standard	deviation.
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3  | RESULTS
3.1 | Patients














Symptomatic	 patients	 had	 a	 similar	 age	 (mean	 64	 vs	 63	years;	






Seventeen	 percent	 of	 patients	with	 bacterascites	were	 diagnosed	






































4	(13%) 11	(10%) 3	(11%) 6	(12%) 3	(5%) 3	(9%)
Healthcare-
associated
15	(48%) 63	(57%) 14	(54%) 35	(67%) 30	(54%) 18	(56%)








26	(84%) 89	(80%) 21	(81%) 39	(75%) 46	(82%) 24	(75%)
Concomitant	infection,	N	(%)
Respiratory	tract 1	(3%) 8	(7%) 0 3	(6%) 7	(12%) 6	(19%)
Skin 1	(3%) 8	(7%) 1	(4%) 6	(12%) 4	(7%) 2	(6%)
Urinary	tract 0 7	(6%) 0 3	(6%) 3	(5%) 4	(12%)
Concomitant	blood	culture,	N	(%)
Non	taken 25	(80%) 65	(59%) 23	(88%) 24	(46%) 27	(48%) 10	(31%)
Negative 3	(10%) 21	(19%) 1	(4%) 13	(25%) 15	(27%) 8	(25%)
Positive 3	(10%) 25	(22%) 2	(8%) 15	(29%) 14	(25%) 14	(44%)
aPatients	could	have	multiple	symptoms	per	episode.	More	details	are	described	in	the	Results	section	in	the	paragraph	Bacterascites.






















Multidrug	 antibiotic-	resistant	 (MDR)	 organisms	 were	 isolated	
in	 25%	 of	 all	 episodes.	 Methicillin-	resistant	 Staphylococci	 were	
the	 most	 frequently	 found	 MDR	 organism	 (N	=	26),	 followed	 by	











(14%)	 and	 vancomycin	 (10%).	 Symptomatic	 patients	 more	 often	
received	 treatment	 compared	 to	 asymptomatic	 patients	 (72%	 vs	
52%;	P = 0.031).	Patients	with	higher	MELD	score	 (HR	1.156	per	
point,	95%CI	1.060-	1.260,	P = 0.001),	higher	PMN	count	in	ascites	
(HR	1.017	per	point,	95%CI	1.005-	1.030,	P = 0.007),	an	 infection	
with	another	bacterial	genus	than	Staphylococci	(HR	3.512,	95%CI	
1.333-	9.253,	 P = 0.011),	 and	 a	 female	 gender	 (HR	 2.837,	 95%CI	
F IGURE  1 Type	of	pathogens	cultured	
in	142	bacterascites	episodes	classified	
























initiated.	 In	31/46	episodes	 (67%),	 patients	 had	 signs	or	 symp-
toms	of	infection.	A	total	of	111	episodes	of	bacterascites	were	
symptomatic.	 The	 ascitic	 PMN	 count	 in	 80	 patients	who	were	
treated	 with	 antibiotics	 was	 significantly	 higher	 (median	 31,	








5/8	 patients	were	 admitted	 at	 the	 ICU;	 either	 before	 paracen-
tesis	 (two	 patients),	 or	 after	 paracentesis	 (three	 patients).	 SBP	
developed	in	six	cases,	and	bacterascites	persisted	in	five	cases.	
The	 latter	 group	 and	 those	 diagnosed	with	 SBP	were	 immedi-
ately	treated	with	antibiotics.	A	logistic	regression	analysis	was	
performed	 in	 the	untreated	patients	 to	 identify	 risk	 factors	 for	
liver-	related	death	before	culture	 results	were	known,	SBP	de-
velopment,	 and	 persisting	 bacterascites	 (19/46)	 compared	 to	
clinical	remission	(27/46).	We	found	that	MELD	score	(HR	1.286	
per	 point,	 95%CI	 1.071-	1.546,	 P = 0.007)	 and	 age	 (HR	 1.113	
per	 year,	 95%CI	1.027-	1.205,	P = 0.009)	were	 independent	 risk	
factors.
3.5 | Clinical course and outcome
The	survival	analyses	included	114	patients	with	bacterascites	and	
88	patients	with	SBP,	after	the	exclusion	of	patients	with	both	SBP	
and	bacterascites.	The	median	 follow-	up	 time	 in	114	patients	was	
38	days	 (IQR	15-	272).	 In	 this	 study	cohort,	27	patients	were	alive	
or	 lost	 to	 follow-	up,	 16	 patients	 received	 a	 liver	 transplant,	 and	
71	patients	died.	The	causes	of	death	were	 in	36	patients	 (50.7%)	
liver	 disease-	related,	 in	 29	 patients	 (40.9%)	 unknown,	 and	 in	 six	
patients	 (8.4%)	a	combination	of	 liver	disease-	related	and	nonliver	
disease-	related.

















Bacterascites without antibiotic treatment
N = 46
Symptomatic bacterascites














































































Number of patients at risk 
114  Bacterascites  
SBP  
29  28 
88 27          
48          
39          
40          




HR 95% CI P- value








































Advanced chronic liver disease and bacterascites 
Advanced chronic liver disease and SBP
Advanced chronic liver disease without ascites infection
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which	has	been	previously	postulated	in	studies	analysing	patients	

















disease	 aetiology	 and	 immunosuppressant	 use.	 Female	 patients	
were	 more	 likely	 to	 have	 autoimmune	 hepatitis,	 primary	 biliary	
cirrhosis,	or	nonalcoholic	 steatohepatitis	 and	more	often	used	 im-




of	bacterascites.	 In	 two-	thirds	of	 the	 cases,	 the	 treating	physician	
decided	to	initiate	antibiotic	treatment.	However,	in	the	46	episodes	






resolved,	 was	 equal	 in	 symptomatic	 and	 asymptomatic	 patients.	




international	 microbiologic	 SBP	 studies	 reporting	 MDR	 bacteria	
rates	 of	 27%-	67%.37-39	 The	 involvement	 of	MDR	 bacteria	 in	 bac-







The	 relatively	high	 rate	of	 short-	term	mortality	 suggests	bacteras-




been	proven	effective	 in	SBP,	seems	appropriate	 in	bacterascites.9 
Taking	 in	 consideration	 that	 27	 of	 the	 46	 untreated	 cases	 of	 bac-











One	 of	 the	 limitations	 of	 this	 study	 is	 that,	 because	 of	 the	 retro-
spective	 design,	 the	 natural	 course	 of	 bacterascites	 could	 not	 be	
optimally	studied.	For	instance,	it	may	well	be	that	patients	received	
antibiotic	 treatment	 while	 the	 bacterascites	 would	 have	 resolved	
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